Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus
Portfolio Pulse from Vandana Singh
Atea Pharmaceuticals Inc (NASDAQ:AVIR) announced promising Phase 2 data for its hepatitis C virus (HCV) therapy, bemnifosbuvir. The study showed a 97% sustained virologic response rate at 12 weeks post-treatment and a 100% response rate in genotype 3 patients. The therapy was well tolerated with no severe adverse events. The company plans to present these findings at the EASL Congress.
June 05, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atea Pharmaceuticals announced positive Phase 2 data for its HCV therapy, bemnifosbuvir, showing a 97% response rate and a 100% response rate in genotype 3 patients. The therapy was well tolerated with no severe adverse events. Shares are up 2.12%.
The positive Phase 2 data for bemnifosbuvir, showing high efficacy and good tolerance, is likely to boost investor confidence and drive the stock price up in the short term. The 2.12% increase in share price reflects this positive sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100